Back to results
US 2018/0002349 A1Published application
New Azabenzimidazole Derivatives
AssigneeBoehringer Ingelheim International GmbH
InventorsFrank HIMMELSBACH, Elke LANGKOPF
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of general formula (I), wherein R1, R2, R3, A1, A2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Claims13
A compound of formula I containing three (consecutive) aromatic or heteroaromatic moieties
- wherein
- A1 is selected from the group consisting of CH, CR2 and N,
- A2 is selected from the group consisting of CH, CF and N,
- R1 is selected from the group consisting of F and Cl,
- R2 is selected from the group consisting of F and methoxy,
- R3 is selected from the group consisting of
- m is selected from an integer consisting of 0, 1 and 2, and
- n is selected from an integer consisting of 0, 1, and 2,
- with the provisos, that at least one substituent attached to an aromatic or heteroaromatic moiety in formula I represents F or that R2 represents methoxy,
- or a salt thereof.
7 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.